The Board of Directors has appointed Jakob Lindberg as Chief Executive Officer, CEO of Oncopeptides.
Jakob Lindberg replaces Marty J Duvall, who has been the CEO since July 1, 2020. These changes are effective immediately.
Returns to being a Sweden based R&D company
The leadership changes follows the withdrawal of Pepaxto (INN melphalan flufenamide) from the US market and the company’s need to focus its resources on research and development on the path ahead.
“Jakob’s unique understanding of the platform technology and drug development will serve the company well for this phase and the journey ahead of us.”
“We are very pleased that Jakob will continue his dedicated engagement in Oncopeptides, and lead the refocus to a Sweden based R&D company. Jakob’s unique understanding of the platform technology and drug development will serve the company well for this phase and the journey ahead of us,” says Per-Wold Olsen, Chairman of Oncopeptides. “I would also like to thank Marty for his relentless focus on commercializing Pepaxto in the US. Unfortunate circumstances led us to where we are and we wish Marty all the best as he pursues new career options outside of Oncopeptides.”
Jakob Lindberg was the CEO of Oncopeptides from the restart of the company in 2011, until June 2020. He has been instrumental in the development of Oncopeptides, and is currently Chief Scientific Officer.
Photo of Jakob Lindberg: Oncopeptides